Close Menu

NEW YORK (GenomeWeb) – CRISPR-based therapy developer Editas Medicine is looking to raise up to $122 million in a planned initial public offering, according to an amended prospectus filed today with the US Securities and Exchange Commission.

According to the amended Form S-1, Editas has registered to sell 5.9 million shares with a proposed price per share between $16 and $18, for a maximum offering price just over $122 million. The firm will also offer 885,000 shares of common stock to the underwriters to cover over-allotments.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.